Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4122804 | 1.00 | TSHR (0.40) | TSHR | |
| SCHEMBL31616404 | 1.00 | TSHR (0.40) | TSHR | |
| SCHEMBL563252 | 1.00 | TSHR (0.40) | TSHR | |
| SCHEMBL30724855 | 1.00 | TSHR (0.40) | TSHR | |
| SCHEMBL1491293 | 1.00 | TSHR (0.40) | TSHR | |
| SCHEMBL2552181 | 1.00 | TSHR (0.40) | TSHR | |
| SCHEMBL18089434 | 1.00 | TSHR (0.40) | TSHR | |
| Hydrochloric Acid SCHEMBL25375836 | 0.97 | TSHR (0.39) | TSHR | |
| SCHEMBL2818899 | 0.95 | — | — | |
| Hydrochloric Acid SCHEMBL25377147 | 0.92 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025133234-A1 | SORTILIN BINDERS AND BIFUNCTIONAL COMPOUNDS THEREOF | DRAUPNIR BIO APS (DK) | 2025-06-26 | — | — | WO | disclosed |
| EP-4543858-A1 | BIFUNCTIONAL MOLECULES THAT SELECTIVELY INDUCE DEGRADATION OF EXTRACELLULAR TARGETS IN LYSOSOMES | Draupnir Bio ApS (DK) | 2025-04-30 | — | — | EP | disclosed |
| US-20250002526-A1 | PHARMACEUTICAL COMPOSITION HAVING ANTI-CANCER IMMUNOSTIMULATING EFFECT AND/OR IMMUNE CHECKPOINT INHIBITION POTENTIATING EFFECT | KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (JP) | 2025-01-02 | — | — | US | disclosed |
| EP-4420666-A1 | PHARMACEUTICAL COMPOSITION HAVING ANTI-CANCER IMMUNOSTIMULATING EFFECT AND/OR IMMUNE CHECKPOINT INHIBITION POTENTIATING EFFECT | Kyushu University, National University Corporation (JP) | 2024-08-28 | — | — | EP | disclosed |
| US-20240165250-A1 | Bifunctional Folate Receptor Binding Compounds | LYCIA THERAPEUTICS, INC. | 2024-05-23 | — | — | US | disclosed |
| CN-117460507-A | Compound targeting fibroblast activation protein and method of use thereof | 普渡研究基金会 | 2024-01-26 | — | — | CN | disclosed |
| WO-2023247754-A1 | BIFUNCTIONAL MOLECULES THAT SELECTIVELY INDUCE DEGRADATION OF EXTRACELLULAR TARGETS IN LYSOSOMES | DRAUPNIR BIO APS (DK) | 2023-12-28 | — | — | WO | disclosed |
| WO-2023225369-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR CELL-SPECIFIC PHARMACOLOGY | DUKE UNIVERSITY (US) | 2023-11-23 | — | — | WO | disclosed |
| EP-4274619-A1 | BIFUNCTIONAL FOLATE RECEPTOR BINDING COMPOUNDS | Lycia Therapeutics, Inc. (US) | 2023-11-15 | — | — | EP | disclosed |
| US-20230190939-A1 | ANTIBODY DRUG CONJUGATES COMPRISING TOXINS WITH POLAR GROUPS AND USES THEREOF | INTOCELL, INC. (KR) | 2023-06-22 | — | — | US | disclosed |
| US-20190111142-A1 | Silanol Based Therapeutic Payloads | BLINKBIO, INC. (US) | 2019-04-18 | — | — | US | disclosed |
| US-20180200273-A1 | Silanol Based Therapeutic Payloads | BLINKBIO INC (US) | 2018-07-19 | — | — | US | disclosed |
| US-9931407-B2 | Silicon based drug conjugates and methods of using same | BLINKBIO, INC. (US) | 2018-04-03 | — | — | US | disclosed |
| US-9931407-B2 | Silicon based drug conjugates and methods of using same | BLINKBIO, INC. (US) | 2018-04-03 | — | — | US | disclosed |
| US-9931407-B2 | Silicon based drug conjugates and methods of using same | BLINKBIO, INC. (US) | 2018-04-03 | — | — | US | disclosed |
| WO-2017214491-A1 | SILANOL BASED THERAPEUTIC PAYLOADS | BLINKBIO, INC. (US) | 2017-12-14 | — | — | WO | disclosed |
| US-20170202970-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | BLINKBIO, INC. | 2017-07-20 | — | — | US | disclosed |
| US-20170202970-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | BLINKBIO, INC. | 2017-07-20 | — | — | US | disclosed |
| US-20170202970-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | BLINKBIO, INC. | 2017-07-20 | — | — | US | disclosed |
| WO-2016183359-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | BLINKBIO, INC. (US) | 2016-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230190939-A1 | ANTIBODY DRUG CONJUGATES COMPRISING TOXINS WITH POLAR GROUPS AND USES THEREOF | CD47, ENPP2, CD2 | TSHR 823/4885 |
| US-20170202970-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | CD44, MSN, AS3MT | TSHR 2393/4885 |
| US-20250002526-A1 | PHARMACEUTICAL COMPOSITION HAVING ANTI-CANCER IMMUNOSTIMULATING EFFECT AND/OR IMMUNE CHECKPOINT INHIBITION POTENTIATING EFFECT | CD274, PDCD1, PDCD1LG2 | TSHR 942/4885 |
| US-20180200273-A1 | Silanol Based Therapeutic Payloads | CD47, CD4, BST2 | TSHR 3437/4885 |
| US-20190111142-A1 | Silanol Based Therapeutic Payloads | CD47, CD4, BST2 | TSHR 3437/4885 |
| US-20240165250-A1 | Bifunctional Folate Receptor Binding Compounds | FOLR1, FOLR2, FOLH1 | TSHR 137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.